Steatosis and Phospholipidosis

Steatosis and Phospholipidosis analysis

The early detection of toxic events induced by drug candidates can help to avoid late attrition during the development process Due to its unique vascular, secretory, synthetic, and metabolic features, the liver is a major target of the toxicity of xenobiotics. Exposition of this organ to drugs can lead to various cellular lesions, like steatosis and phospholipidosis. Steatosis corresponds to an accumulation of triglicerids within liver cells, which may lead to steatohepatitis. Phospholipidosis isdue to aisruption inphospholipidase enzymatic activity, leading to intracellular phospholipid accumulation. Although not a toxic event by itself, phospholipidosis can predict drug and metabolite accumulation that may provoke toxicity within the liver (or the kidney). Drug-induced steatosis and phospholipidosis can be quantified by High Content Screening.

To learn more on these assays, see also our posters presented in different congress:


  • Compounds: powder or stock solution
  • Cells:  HepG2 or HepaRG cell lines,  primary hepatocytes, with or without S9 if required
  • Plate format: 96 or 384-well plates

Few examples of reference compounds

Don’t hesitate to ask for our short report on HepG2 cells exposed to ENZO hepatotoxicity library !